ImageneBio, Inc. (IMA)
NASDAQ: IMA · Real-Time Price · USD
5.25
-0.40 (-7.08%)
May 19, 2026, 4:00 PM EDT - Market closed
Company Description
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases.
Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial.
The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025.
ImageneBio, Inc. is headquartered in San Diego, California.
ImageneBio, Inc.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Kristin Yarema |
Contact Details
Address: 12526 High Bluff Drive, Suite 345 San Diego, California 92130 United States | |
| Phone | 858 345 6265 |
| Website | inmagenebio.com |
Stock Details
| Ticker Symbol | IMA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001835579 |
| CUSIP Number | 45175G207 |
| ISIN Number | US45175G2075 |
| Employer ID | 81-1697316 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kristin Yarema Ph.D. | Chief Executive Officer, Director and Interim Principal Financial Officer |
| Bob Lally | Senior Vice President of Finance and Operations and Principal Accounting Officer |
| Dr. Kurinji Pandiyan Ph.D. | Chief Strategy and Operations Officer |
| Renuka Sivendran Ph.D. | Chief Technical Officer |
| Dr. Benjamin Porter-Brown M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 14, 2026 | SCHEDULE 13G/A | Filing |
| May 8, 2026 | 424B3 | Prospectus |
| May 7, 2026 | 424B3 | Prospectus |
| May 7, 2026 | 10-Q | Quarterly Report |
| May 7, 2026 | 8-K | Current Report |
| Apr 30, 2026 | ARS | Filing |
| Apr 30, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 29, 2026 | SCHEDULE 13D/A | Filing |